Upstream Bio, Inc. (UPB): who owns it and who trades it
As of Nov 16, 2026, UPB insiders reported 15 open-market sales worth $105K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Everett Rand Sutherland (CEO), with $43.7K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Upstream Bio
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns UPB
148 funds and institutions reported UPB shares worth $352M at the end of Q2 2026, about 93% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) 93%Everyone else 7%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 8.16M | 15.00% | $56.5M | +1% |
| Orbimed Advisors LLC | 5.69M | 10.46% | $39.4M | No change |
| Norges Bank | 3.77M | 6.93% | $26.1M | – |
| BlackRock, Inc. | 3.75M | 6.90% | $26M | +11% |
| Decheng Capital LLC | 2.72M | 5.01% | $18.9M | No change |
| Enavate Sciences Gp, LLC | 2.46M | 4.52% | $17M | No change |
| Vanguard Capital Management LLC | 1.88M | 3.45% | $13M | +0% |
| Millennium Management LLC | 1.14M | 2.10% | $7.9M | +22% |
| D. E. Shaw & Co., Inc. | 1.04M | 1.90% | $7.2M | +26% |
| JPMorgan Chase & Co | 1.01M | 1.86% | $7M | – |
| Qube Research & Technologies Ltd | 978,500 | 1.80% | $6.8M | +58% |
| Parkman Healthcare Partners LLC | 935,247 | 1.72% | $6.5M | +19% |
| Geode Capital Management, LLC | 931,261 | 1.71% | $6.4M | -2% |
| SEB Asset Management AB | 878,473 | 1.61% | $6.1M | No change |
| Woodline Partners LP | 831,481 | 1.53% | $5.8M | No change |
| State Street Corp | 766,323 | 1.41% | $5.3M | +9% |
| Vanguard Portfolio Management LLC | 712,667 | 1.31% | $4.9M | -2% |
| Y-Intercept (Hong Kong) Ltd | 693,555 | 1.27% | $4.8M | -31% |
| Bain Capital Life Sciences Investors, LLC | 600,949 | 1.10% | $4.2M | -31% |
| AQR Capital Management LLC | 544,869 | 1.00% | $3.8M | +655% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, UPB insiders reported $0 of open-market purchases and $105K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Aaron Deykin | Chief Medical Officer | Sale | 895 | $5.49 | $4.9K | Form 4 |
| Sep 16, 2026 | Everett Rand Sutherland | CEO | Sale | 2,095 | $5.49 | $11.5K | Form 4 |
| Sep 16, 2026 | Adam Houghton | Chief Business Officer | Sale | 700 | $5.49 | $3.8K | Form 4 |
| Sep 16, 2026 | Michael Gray | CFO | Sale | 853 | $5.49 | $4.7K | Form 4 |
| Sep 16, 2026 | Allison Ambrose | General Counsel | Sale | 485 | $5.49 | $2.7K | Form 4 |
| Jun 16, 2026 | Michael Gray | CFO | Sale | 853 | $6.10 | $5.2K | Form 4 |
| Jun 16, 2026 | Everett Rand Sutherland | CEO | Sale | 2,095 | $6.10 | $12.8K | Form 4 |
| Jun 16, 2026 | Adam Houghton | Chief Business Officer | Sale | 700 | $6.10 | $4.3K | Form 4 |
| Jun 16, 2026 | Aaron Deykin | Chief Medical Officer | Sale | 895 | $6.10 | $5.5K | Form 4 |
| Jun 16, 2026 | Allison Ambrose | General Counsel | Sale | 477 | $6.10 | $2.9K | Form 4 |
| Mar 16, 2026 | Michael Gray | CFO | Sale | 852 | $9.29 | $7.9K | Form 4 |
| Mar 16, 2026 | Aaron Deykin | Chief Medical Officer | Sale | 894 | $9.29 | $8.3K | Form 4 |
| Mar 16, 2026 | Everett Rand Sutherland | CEO | Sale | 2,093 | $9.29 | $19.4K | Form 4 |
| Mar 16, 2026 | Allison Ambrose | General Counsel | Sale | 475 | $9.29 | $4.4K | Form 4 |
| Mar 16, 2026 | Adam Houghton | Chief Business Officer | Sale | 699 | $9.29 | $6.5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Everett Rand Sutherland | Chief Executive Officer, Director | – | $43.7K | Sep 16, 2026 |
| Aaron Deykin | Chief Medical Officer | – | $18.7K | Sep 16, 2026 |
| Michael Gray | CFO and COO | – | $17.8K | Sep 16, 2026 |
| Adam Houghton | Chief Business Officer | – | $14.6K | Sep 16, 2026 |
| Allison Ambrose | General Counsel | – | $10K | Sep 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
UPB short interest
Moderate short interest. 6.5% of UPB shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 4%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.55M UPB shares were sold short, 6.5% of the shares outstanding, down 20.8% from the report before. At the average daily volume of 1.32M shares, buying them all back would take about 2.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.55M | 6.48% | -21% | 1.32M | 2.7 |
| Oct 15, 2026 | 4.48M | 8.18% | -1% | 1.22M | 3.7 |
| Sep 30, 2026 | 4.51M | 8.24% | +1% | 587,966 | 7.7 |
| Sep 15, 2026 | 4.49M | 8.20% | +10% | 656,192 | 6.8 |
| Aug 31, 2026 | 4.10M | 7.48% | +2% | 549,503 | 7.5 |
| Aug 14, 2026 | 4.02M | 7.33% | +10% | 712,393 | 5.6 |
| Jul 31, 2026 | 3.65M | 6.70% | +1% | 486,961 | 7.5 |
| Jul 15, 2026 | 3.62M | 6.65% | -12% | 442,098 | 8.2 |
| Jun 30, 2026 | 4.11M | 7.54% | +5% | 718,338 | 5.7 |
| Jun 15, 2026 | 3.90M | 7.16% | +7% | 711,476 | 5.5 |
| May 29, 2026 | 3.64M | 6.69% | +7% | 534,404 | 6.8 |
| May 15, 2026 | 3.40M | 6.24% | +5% | 507,812 | 6.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Upstream Bio company events
Upstream Bio filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Sep 1, 2026AnnouncementThe Company announced its pivotal Phase 3 development plans for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Mar 26, 2026AgreementUpstream Bio, Inc. entered into a Sales Agreement with Leerink Partners LLC, as sales agent, pursuant to which the Company from time to time may offer and sell shares of its common stock, par value $0.001 per share, through or to the Agent. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Feb 11, 2026ResultsReleased financial results. Filing
- Feb 11, 2026AnnouncementThe Company announced positive top-line data from the Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group VALIANT clinical trial (NCT06196879) that evaluated the safety and efficacy of verekitug for up to 60 weeks, with a minimum of 24 weeks of treatment, in… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Upstream Bio financials
Famous investors that hold UPB
5 of the 50 well-known investors we track reported holding UPB in their latest 13F filing. The largest position is Israel Englander's, worth $6.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.17M | $6.2M | 0.0% | +2% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 372,823 | $2M | 0.0% | -18% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 194,700 | $1M | 0.0% | +48% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 59,042 | $311K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 26,755 | $141K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named UPB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 6, 2026 | FMR LLC | 13G/A | 6.9% |
| Nov 6, 2026 | FMR LLC | 13G/A | 6.9% |
| Oct 29, 2026 | Decheng Capital Global Life Sciences Fund IV, L.P. | 13G/A | 4.9% |
| Oct 29, 2026 | Decheng Capital Global Life Sciences Fund IV, L.P. | 13G/A | 4.9% |
Questions about Upstream Bio, Inc. (UPB) stock
Who owns the most UPB stock?
The largest reported owner of Upstream Bio, Inc. (UPB) is FMR LLC (Fidelity), with 15.0% of the company. In total, 148 funds and institutions reported holding UPB at the end of Q2 2026, together about 93% of the shares. See the largest owners.
Are UPB insiders buying or selling?
In the last 12 months, UPB insiders reported no open-market purchases and 15 sales worth $105K. The latest trade was on Sep 16, 2026. See every trade.
What is the short interest in UPB?
As of Oct 30, 2026, 3.55M UPB shares were sold short, 6.5% of the shares outstanding, down 20.8% from the report before. At the average daily volume of 1.32M shares, buying them all back would take about 2.7 trading days (days to cover). See the history.
Which famous investors hold UPB?
5 of the 50 well-known investors we track reported UPB in their latest 13F filing, including Israel Englander, Steve Cohen, Jim Simons. The largest position is worth $6.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.